Merus N Vis A Clinical Stage Immuno Oncology Company Based In Utrechtthe Netherlandsfounded In 2003The Company Is Dedicated To Developing Innovative Antibody Therapeutics To Meet The Needs Of Cancer Treatmentmerus Went Public In 2016 And Has Around 321 Employeeswith Operations In Both The Netherlands And The U S The Company Utilizes Proprietary Platforms To Create Multispecific Antibodiesincluding Biclonicsa Triclonicsa And Multiclonicsa Its Clinical Pipeline Features Several Candidatessuch As Petosemtamabmcla 158For Head And Neck Squamous Cell Carcinomamcla 129 For Non Small Cell Lung Cancerand Ono 4685Developed In Collaboration With Ono Pharmaceuticalmerus Has Strategic Partnerships With Eli Lilly And Ono Pharmaceuticalfocusing On Advancing Bispecific Antibody Development And Other Therapeutic Candidates Merus Aims To Discover Immune System Based Therapeutics That Significantly Improve The Lives Of Cancer Patientswith A Vision To Deliver Meaningful Clinical Advancements Through Its Innovative Antibody Treatments
No conferences found for this company.
| Company Name | Merus Nv |
| Country |
Netherlands
|
| Address | N/A |
| Telephone | N/A |
| N/A |
